Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360347 | 0.94 | SMN1; SMN2 (0.41) | TDP1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1361767 | 0.93 | MAPT (0.38) | TDP1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1361965 | 0.93 | TDP1 (0.35) | TDP1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1361656 | 0.91 | MAPT (0.39) | TDP1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL203742 | 0.90 | TP53 (0.41) | TDP1MAPTSMN1; SMN2L3MBTL1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1362475 | 0.90 | TP53 (0.41) | TDP1MAPTSMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL1362037 | 0.88 | PPARD (0.39) | SMN1; SMN2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL7507030 | 0.88 | PPARD (0.41) | TDP1MAPTRAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL1362923 | 0.88 | MAPT (0.42) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL1363057 | 0.87 | MAPT (0.39) | TDP1MAPTRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269219-A1 | Neurotrophin production/secretion promoting agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | claimed |
| EP-1206472-B1 | OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-10-01 | — | — | EP | claimed |
| US-6605629-B1 | Oxazole derivatives; low toxicity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-12 | — | — | US | claimed |
| EP-1206472-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT | Takeda Chemical Industries, Ltd. (JP) | 2002-05-22 | — | — | EP | claimed |
| WO-2001014372-A2 | OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-01 | — | — | WO | claimed |
| EP-1491194-B1 | VDAC REGULATOR | TAKEDA PHARMACEUTICAL (JP) | 2013-10-30 | — | — | EP | disclosed |
| US-8067453-B2 | Oxazole compound to treat or prevent diabetic neuropathy; 4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl-2-methyl-1-imidazolyl)oxazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-29 | — | — | US | disclosed |
| US-7498352-B2 | TGF-β superfamily production/secretion promoter | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-03 | — | — | US | disclosed |
| US-7462635-B2 | Thiazole and oxazole VDAC regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-20080269219-A1 | Neurotrophin production/secretion promoting agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-7396848-B1 | oxazole derivatives to treat diabetic neuropathy and/or other kinds of peripheral neuropathy; 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-08 | — | — | US | disclosed |
| US-20050234116-A1 | Vdac regulator | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2005-10-20 | — | — | US | disclosed |
| EP-1206472-B1 | OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-10-01 | — | — | EP | disclosed |
| US-6605629-B1 | Oxazole derivatives; low toxicity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-12 | — | — | US | disclosed |
| EP-1196398-A4 | BRIDGED FLUORESCENT DYES, THEIR PREPARATION AND THEIR USE IN ASSAYS | SURROMED INC (US) | 2002-11-06 | — | — | EP | disclosed |
| US-6403807-B1 | CYANINE DYES HAVING SEPARATE SECOND LINKING CHAIN JOINING TWO HETEROCYCLES TO RESTRAIN COMPOUND INTO DESIRED CONFORMATION WHICH ABSORBS ELECTROMAGNETIC ENERGY AND EMITS FLUORESCENCE AT SPECIFIED WAVELENGTHS | SURROMED, INC. | 2002-06-11 | — | — | US | disclosed |
| EP-1206472-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT | Takeda Chemical Industries, Ltd. (JP) | 2002-05-22 | — | — | EP | disclosed |
| EP-1196398-A1 | BRIDGED FLUORESCENT DYES, THEIR PREPARATION AND THEIR USE IN ASSAYS | Surromed, Inc. (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001014372-A2 | OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-01 | — | — | WO | disclosed |
| WO-2001002374-A1 | BRIDGED FLUORESCENT DYES, THEIR PREPARATION AND THEIR USE IN ASSAYS | SURROMED, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269219-A1 | Neurotrophin production/secretion promoting agent | BDNF, NGF, NTRK2 | TDP1 3338/4885MAPT 3908/4885RAB9A 3500/4885 |
| US-20050234116-A1 | Vdac regulator | VDAC1, VDAC2, VDAC3 | TDP1 2942/4885MAPT 3373/4885RAB9A 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.